Origin Materials (ORGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Jun, 2026Executive summary
Board approved a plan for complete dissolution and liquidation, pending shareholder approval at a special meeting on July 1, 2026.
Voluntary delisting from Nasdaq and deregistration with the SEC are planned, with Form 25 to be filed around June 22, 2026, and delisting effective July 2, 2026.
Warrants will expire on June 24, 2026, and will be delisted accordingly.
After delisting, trading may occur on the OTC market, but no application will be made for OTC quotation.
If dissolution is approved and a certificate of dissolution is filed, no trading market will exist for the common stock.
Voting matters and shareholder proposals
Shareholders will vote on the Plan of Dissolution at a special meeting scheduled for July 1, 2026.
Proxy materials and related documents are available for shareholders to review prior to voting.
Board of directors and corporate governance
The board determined that delisting and dissolution align with the goal of maximizing shareholder value, including the sale of technology and assets.
Information on directors and executive officers, including their interests, is included in the proxy statement and annual report amendment.
Latest events from Origin Materials
- Stockholders to vote on dissolution and liquidation, with estimated payouts of $0.61–$3.54 per share.ORGN
Proxy filing26 May 2026 - Stockholders will vote on a plan to dissolve the company and distribute $0.61–$3.54 per share.ORGN
Proxy filing15 May 2026 - Stockholders will vote on a proposed dissolution, with estimated payouts of $0.61–$3.48 per share.ORGN
Proxy filing14 May 2026 - Dissolution plan approved, operations winding down, and Q1 revenue fell 91% year-over-year.ORGN
Q1 202614 May 2026 - Breakeven delayed to 2028 as PET cap commercialization progresses amid urgent liquidity needs.ORGN
Q4 202527 Mar 2026 - Stockholders approved a reverse split and major share issuance, advancing strategic milestones.ORGN
EGM 202618 Feb 2026 - $100M+ PET cap deal signed; Q2 loss $19.5M; Q4 2024 production on track.ORGN
Q2 20241 Feb 2026 - Strong PET cap demand, $100M+ MOU, and EBITDA positivity targeted for 1H 2026.ORGN
Q3 202414 Jan 2026 - Rapid transformation to PET caps leverages technical strengths, innovation, and scalable growth.ORGN
Fireside Chat9 Jan 2026